Company Description
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases.
Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Brent Pfeiffenberger |
Contact Details
Address: 25 North 38th Street, 11th Floor Philadelphia, Pennsylvania 19104 United States | |
| Phone | 267 817 5790 |
| Website | centurytx.com |
Stock Details
| Ticker Symbol | IPSC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001850119 |
| CUSIP Number | 15673T100 |
| ISIN Number | US15673T1007 |
| Employer ID | 84-2040295 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | President, Chief Executive Officer and Chairman |
| Dr. Gregory Russotti Ph.D. | Chief Technology and Manufacturing Officer |
| Douglas Carr CPA | Senior Vice President of Finance and Operations, Principal Financial Officer and Secretary |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer |
| Krista Kauppinen J.D., Ph.D. | Vice President, General Counsel and Head of Intellectual Property |
| Megan Bilson | Chief People Officer |
| Michael Naso Ph.D. | Senior Vice President of Cell Engineering |
| Elizabeth Devlin | Vice President and Head of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2026 | ARS | Filing |
| Apr 16, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 26, 2026 | 424B5 | Filing |
| Mar 12, 2026 | 144 | Filing |
| Mar 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 10-K | Annual Report |